Martine Zimmermann's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 5,783 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals, In... | Martine Zimmermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Martine Zimmermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 4,746 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Martine Zimmermann | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.99 per share. | 06 Jun 2025 | 188 | 4,558 (0%) | 0% | 106.0 | 19,926 | Common Stock |
| Ligand Pharmaceuticals, In... | Martine Zimmermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Martine Zimmermann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 3,537 (0%) | 0% | 0 | Common Stock |